Integrated Diagnostics Holdings PLC
LSE:IDHC

Watchlist Manager
Integrated Diagnostics Holdings PLC Logo
Integrated Diagnostics Holdings PLC
LSE:IDHC
Watchlist
Price: 0.599 USD -0.17% Market Closed
Market Cap: $348.2m

Operating Margin

22.9%
Current
Improving
by 4.3%
vs 3-y average of 18.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
22.9%
=
Operating Income
2.1B
/
Revenue
9.3B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
22.9%
=
Operating Income
$2.1B
/
Revenue
9.3B

Peer Comparison

Country Company Market Cap Operating
Margin
JE
Integrated Diagnostics Holdings PLC
LSE:IDHC
348.2m USD
Loading...
US
CVS Health Corp
NYSE:CVS
93.1B USD
Loading...
US
Cigna Group
XMUN:CGN
67.2B EUR
Loading...
US
Cigna Corp
NYSE:CI
72.6B USD
Loading...
DE
Fresenius SE & Co KGaA
XETRA:FRE
24.3B EUR
Loading...
DE
Fresenius Medical Care AG
XMUN:FME
22.5B EUR
Loading...
US
Laboratory Corporation of America Holdings
NYSE:LH
22.6B USD
Loading...
US
Quest Diagnostics Inc
NYSE:DGX
21.9B USD
Loading...
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
10.9B EUR
Loading...
US
Guardant Health Inc
NASDAQ:GH
11.7B USD
Loading...
US
DaVita Inc
NYSE:DVA
10.3B USD
Loading...

Market Distribution

Higher than 87% of companies in Jersey
Percentile
87th
Based on 93 companies
87th percentile
22.9%
Low
-71% — -0.3%
Typical Range
-0.3% — 0.3%
High
0.3% — 1 083.5%
Distribution Statistics
Jersey
Min -71%
30th Percentile -0.3%
Median -0.2%
70th Percentile 0.3%
Max 1 083.5%

Integrated Diagnostics Holdings PLC
Glance View

Market Cap
348.2m USD
Industry
Health Care

Integrated Diagnostics Holdings Plc engages in the provision of diagnostics services including pathology and molecular diagnostics, genetics testing and basic radiology to patients and other laboratories. The firm operates in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The company is engaged in offering services in immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology and radiology. Its brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan), and Echo-Lab (Nigeria). The company operates in approximately 507 branches. IDH offers 2,000 diagnostic pathology tests ranging from routine to advanced. Its common tests include those for cholesterol, diabetes, pregnancy, and substance abuse. Through Al Borg Scan, it offers a range of radiology services, including but not limited to magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, x-ray, mammograms, cath lab facilities, and positron emission tomography-computed tomography (PET-CT).

IDHC Intrinsic Value
1.11 USD
Undervaluation 46%
Intrinsic Value
Price $0.599
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
22.9%
=
Operating Income
2.1B
/
Revenue
9.3B
What is Integrated Diagnostics Holdings PLC's current Operating Margin?

The current Operating Margin for Integrated Diagnostics Holdings PLC is 22.9%, which is above its 3-year median of 18.7%.

How has Operating Margin changed over time?

Over the last 3 years, Integrated Diagnostics Holdings PLC’s Operating Margin has decreased from 36% to 22.9%. During this period, it reached a low of 15.2% on Jun 30, 2023 and a high of 36% on Jun 30, 2022.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett